After spending much of the past six months at a four-star rank, medical-equipment specialist Accuray
The maker of the advanced CyberKnife robotic radiosurgery system has seen a pickup in orders as more users adopt the technology, leading to more bullish CAPS calls lately. In its second fiscal quarter, the company boosted its backlog by 18 orders and installed 11 new systems, bringing its installed base around the world to 190 systems. On top of the success in new orders and placements, Accuray reported a big jump in service revenue, which it expects will continue to grow as its installed base of CyberKnife units grows worldwide. Similar to the brighter outlooks coming from medical-device and medical-equipment makers Medtronic
While larger medical-device maker Boston Scientific
Do you think Accuray deserves its raised status? Add your thoughts in the comments box below on this page, or head over to CAPS to rate the company and check out all the information and opinions the community offers, absolutely free.
Always looking ahead, the Motley Fool Rule Breakers service is picking the next generation's big winners today. To see what other rule-breaking stocks David Gardner is recommending now, take a free 30-day trial.
Fool contributor Dave Mock recently upgraded his poker face with some nervous twitches. He owns no shares of the companies mentioned here. Intuitive Surgical is a Rule Breakers pick. Johnson & Johnson is an Income Investor pick. The Fool owns shares of and has written puts on Medtronic. Motley Fool Options has recommended a buy calls position on Johnson & Johnson. The Fool's disclosure policy was overwhelmed by its nomination for an Oscar, and thanks all the little people who have made it the policy it is today.
More from The Motley Fool
Why Accuray Incorporated Is Tumbling 12.5% Today
Fiscal fourth-quarter financials did little to reignite enthusiasm in the cancer treatment company.
Better Buy: Intuitive Surgical, Inc. vs. Accuray Incorporated
Either stock could be a big winner, but right now, it's no contest.
Why Northwest Biotherapeutics, Accuray, and U.S. Steel Slumped Today
Even though the market kept climbing Wednesday, these three stocks couldn't keep up. Find out why.